MBX Biosciences (MBX) vs NewAmsterdam Pharma N.V. (NAMS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MBX Biosciences (MBX) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 235.8% versus a loss of 35.3%. MBX Biosciences is the larger company by market cap ($2.56 billion vs $2.49 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBX | NAMS |
|---|---|---|
| Share price | $53.25 | $21.26 |
| Market cap | $2.56B | $2.49B |
| 1-day change | -2.37% | -3.93% |
| YTD return | +68.83% | -39.40% |
| 1-year return | +235.75% | -35.30% |
| 5-year return | — | +117.16% |
| EPS (TTM) | $-2.37 | $-2.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $22.50M |
| Revenue growth (YoY) | — | -50.61% |
| Net income (latest FY) | $-87.00M | $-203.82M |
| Operating margin | — | -1002.90% |
| Net margin | — | -905.74% |
| 52-week high | $72.64 | $42.21 |
| 52-week low | $12.94 | $20.91 |
| Distance from 52-week high | -26.69% | -49.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +77.09% | +133.54% |
| Average volume | 539.34K | 1.36M |
| Shares outstanding | 48.16M | 116.90M |
| Employees | 63 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed NAMS by 271.1 percentage points over the past year.
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
MBX vs NAMS FAQ
Which is bigger, MBX Biosciences or NewAmsterdam Pharma N.V.?
MBX Biosciences (MBX) is larger, with a market capitalization of $2.56B compared with $2.49B for NewAmsterdam Pharma N.V. (NAMS).
Which stock has performed better over the past year, MBX or NAMS?
MBX returned +235.75% over the past 12 months, compared with -35.30% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are MBX Biosciences and NewAmsterdam Pharma N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.